Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy

摘要

Disclosed are antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly non-nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays. Particularly disclosed are tests and test vectors relating to HIV reverse transcriptase with mutations at codon 106, 181, 190, 225, 260, 236, that cause a reduction in delavirdine susceptibility and no significant change in nevirapine susceptibility. They may have additional mutations, or more than one of the indicated mutations.